Suzhou Sepax Technologies
688758
Juneway Electronic Technology
301458
Jiujiang Defu Technology
301511
Cubic Digital Technology
300344
Ningbo Shuanglin Auto Parts
300100
CN Stock MarketDetailed Quotes
688117 ChengDu Sheng Nuo Biotec
- 23.33
- -0.43-1.81%
Post Market Jan 10 15:00 CST
2.62BMarket Cap28.35P/E (TTM)
23.95High23.09Low11.72KlotVolume23.87Open23.76Pre Close27.63MTurnover1.04%Turnover Ratio37.27P/E (Static)112.42MShares36.9852wk High2.83P/B2.62BFloat Cap16.2652wk Low28.51Limit Up112.42MShs Float57.26Historical High19.01Limit Down3.62%Amplitude14.38Historical Low0.20Dividend TTM23.57Avg Price4.71KlotAsk0.86%Div YieldTTM100Lot Size4.82KlotBid
ChengDu Sheng Nuo Biotec News
Shengnuo Biotech: Notice on Changing the Company\'s Registered Capital, Revising the “Articles of Association”, and Registering Industrial and Commercial Changes
Notice on the Company and Actual Controllers Providing Guarantees for Wholly-owned Subsidiaries to Apply for Comprehensive Bank Credit Lines
Notice on changing the registered capital of the company, amending the “Articles of Association”, and applying for registration of industrial and commercial changes
Basic information on Chengdu Shengnuo Biopharmaceutical Co., Ltd. and financial statements of June 30, 2024
Shengnuo Biotech: Announcement on the extension of some fund-raising investment projects
Basic information on Chengdu Shengnuo Biopharmaceutical Co., Ltd. and financial statements of June 30, 2024
Notice on the company increasing the guarantee amount for wholly-owned subsidiaries to apply for comprehensive bank credit in 2024
Announcement on the postponement of some fund-raising investment projects
Shengnuo Biotech: Announcement on the signing of a major contract for daily operation by a wholly-owned subsidiary
Announcement on the signing of a major contract for daily operation by a wholly-owned subsidiary
Voluntary Disclosure Notice on Signing Overseas “Investment Cooperation Agreements”
Announcement Regarding the Delay of Some Raised Capital Investment Projects
Announcement regarding voluntary disclosure of the approval notice for the listing application of Citric Acid Compound Betavit Manufacture Active Pharmaceutical Ingredient
Basic information and Q1 2024 financial statements of Chengdu Shengnuo Biopharmaceutical Co., Ltd.
Basic information and Q1 financial statements for Chengdu Shengnuoke Peptide Drug Research Co., Ltd. in 2024.
Notice on the company increasing the guarantee amount for wholly-owned subsidiaries to apply for comprehensive bank credit in 2024
Basic information on Chengdu Shengnuo Biopharmaceutical Co., Ltd. and financial statements for the first quarter of 2024
Legal Opinion of Beijing Hairun Tianrui Law Firm on the 2023 Annual General Meeting of Shareholders of Chengdu Shengnuo Biotechnology Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
2023 Annual General Meeting of Shareholders Meeting Materials
